SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System
SS Innovations (NASDAQ: SSII) has achieved a significant milestone with its SSi Mantra surgical robotic system, successfully completing over 4,000 robotic surgeries across more than 100 types of procedures with zero complications. Notable achievements include 215 cardiac surgical procedures, with six performed via telesurgery across India using the SSi Mantra 3 system.
The system is currently approved in seven countries including India, Nepal, Ecuador, Guatemala, Philippines, Indonesia, and Ukraine. The company is pursuing market expansion with expected European Union CE Mark decision by late 2025 and FDA approval targeted for first half of 2026. The SSi Mantra system supports various surgical specialties including general surgery, urology, gynecology, cardiac, gastrointestinal, thoracic, head and neck, and breast and plastic procedures.
SS Innovations (NASDAQ: SSII) ha raggiunto un traguardo importante con il suo sistema chirurgico robotico SSi Mantra, completando con successo oltre 4.000 interventi chirurgici robotici in più di 100 tipologie di procedure senza complicazioni. Tra i risultati di rilievo figurano 215 interventi chirurgici cardiaci, di cui sei eseguiti tramite telesurgery in tutta l'India utilizzando il sistema SSi Mantra 3.
Il sistema è attualmente approvato in sette paesi, tra cui India, Nepal, Ecuador, Guatemala, Filippine, Indonesia e Ucraina. L'azienda sta puntando all'espansione del mercato con la prevista decisione sulla marcatura CE nell'Unione Europea entro la fine del 2025 e l'approvazione FDA prevista per la prima metà del 2026. Il sistema SSi Mantra supporta diverse specialità chirurgiche, tra cui chirurgia generale, urologia, ginecologia, cardiologia, gastroenterologia, toracica, testa e collo, oltre a interventi di chirurgia plastica e mammaria.
SS Innovations (NASDAQ: SSII) ha alcanzado un hito significativo con su sistema quirúrgico robótico SSi Mantra, completando con éxito más de 4,000 cirugías robóticas en más de 100 tipos de procedimientos sin complicaciones. Logros destacados incluyen 215 procedimientos quirúrgicos cardíacos, de los cuales seis se realizaron mediante telesurgery en toda la India utilizando el sistema SSi Mantra 3.
El sistema está aprobado actualmente en siete países, incluyendo India, Nepal, Ecuador, Guatemala, Filipinas, Indonesia y Ucrania. La empresa busca expandir su mercado con la decisión esperada de la marca CE en la Unión Europea para finales de 2025 y la aprobación de la FDA prevista para la primera mitad de 2026. El sistema SSi Mantra soporta diversas especialidades quirúrgicas, incluyendo cirugía general, urología, ginecología, cardiología, gastrointestinal, torácica, cabeza y cuello, así como procedimientos de mama y cirugía plástica.
SS Innovations(NASDAQ: SSII)는 SSi Mantra 수술용 로봇 시스템으로 중요한 이정표를 달성했으며, 100개 이상의 다양한 수술 절차에서 4,000건 이상의 로봇 수술을 무사고로 성공적으로 완료했습니다. 주목할 만한 성과로는 215건의 심장 수술이 있으며, 그중 6건은 인도 전역에서 SSi Mantra 3 시스템을 사용한 원격 수술로 진행되었습니다.
이 시스템은 현재 인도, 네팔, 에콰도르, 과테말라, 필리핀, 인도네시아, 우크라이나 등 7개국에서 승인받았습니다. 회사는 2025년 말까지 유럽연합 CE 마크 승인 결정을 기대하고 있으며, 2026년 상반기에는 FDA 승인을 목표로 시장 확대를 추진 중입니다. SSi Mantra 시스템은 일반 외과, 비뇨기과, 산부인과, 심장, 위장, 흉부, 두경부, 유방 및 성형 수술 등 다양한 외과 전문 분야를 지원합니다.
SS Innovations (NASDAQ : SSII) a franchi une étape importante avec son système chirurgical robotique SSi Mantra, ayant réalisé avec succès plus de 4 000 interventions chirurgicales robotisées couvrant plus de 100 types de procédures, sans aucune complication. Parmi les réalisations notables figurent 215 interventions chirurgicales cardiaques, dont six effectuées par téléchirurgie à travers l'Inde avec le système SSi Mantra 3.
Le système est actuellement approuvé dans sept pays, dont l'Inde, le Népal, l'Équateur, le Guatemala, les Philippines, l'Indonésie et l'Ukraine. L'entreprise vise une expansion du marché avec une décision attendue pour la certification CE de l'Union européenne d'ici fin 2025 et une approbation FDA prévue pour le premier semestre 2026. Le système SSi Mantra prend en charge diverses spécialités chirurgicales, notamment la chirurgie générale, l'urologie, la gynécologie, la cardiologie, la gastro-entérologie, la chirurgie thoracique, la tête et le cou, ainsi que les interventions mammaires et plastiques.
SS Innovations (NASDAQ: SSII) hat mit seinem chirurgischen Robotersystem SSi Mantra einen wichtigen Meilenstein erreicht und erfolgreich über 4.000 robotergestützte Operationen in mehr als 100 verschiedenen Verfahren ohne Komplikationen abgeschlossen. Bemerkenswerte Erfolge umfassen 215 kardiologische Operationen, von denen sechs mittels Telesurgery in ganz Indien mit dem SSi Mantra 3 System durchgeführt wurden.
Das System ist derzeit in sieben Ländern zugelassen, darunter Indien, Nepal, Ecuador, Guatemala, die Philippinen, Indonesien und die Ukraine. Das Unternehmen strebt eine Markterweiterung an, mit einer erwarteten CE-Kennzeichnungsentscheidung der Europäischen Union bis Ende 2025 und einer FDA-Zulassung, die für die erste Hälfte des Jahres 2026 geplant ist. Das SSi Mantra System unterstützt verschiedene chirurgische Fachgebiete, darunter Allgemeinchirurgie, Urologie, Gynäkologie, Kardiologie, Gastroenterologie, Thoraxchirurgie, Kopf-Hals-Chirurgie sowie Brust- und plastische Chirurgie.
- Milestone of 4,000 successful surgeries with zero complications, injuries, or mortalities
- Market leadership in India with growing physician acceptance
- Cleared for marketing in seven countries
- Advanced capabilities demonstrated through successful telesurgery procedures
- Potential market expansion with pending EU and US approvals
- Regulatory approvals for major markets (US and EU) still pending
- Limited current market presence, operating in only seven smaller markets
Insights
SS Innovations reaches 4,000 surgery milestone with SSi Mantra system, demonstrating market traction ahead of US/EU regulatory decisions.
The announcement of 4,000 successful surgeries with the SSi Mantra robotic system represents a significant operational milestone for SS Innovations. What's particularly impressive is the zero complications reported across this substantial case volume, spanning over 100 surgery types across multiple specialties. This demonstrates robust real-world validation of the platform's safety and versatility.
The 215 cardiac procedures highlighted deserve special attention as cardiac surgery represents one of the most complex and high-risk surgical domains. The successful execution of 6 telesurgery cardiac cases further showcases the system's advanced capabilities and potential for addressing geographical healthcare disparities.
From a market perspective, SS Innovations has established regulatory clearance in 7 countries, primarily emerging markets. The company's stated timeline for regulatory approvals in major markets - EU CE Mark by late 2025 and FDA approval by H1 2026 - provides concrete catalysts for potential market expansion.
The company's focus on affordability and accessibility differentiates it in the surgical robotics market, which has historically been dominated by premium-priced systems with high per-procedure costs. This positions SS Innovations to potentially capture market share in price-sensitive healthcare systems and developing regions where robotic surgery adoption has lagged.
The breadth of surgical applications - from general surgery to cardiac, gynecology, and head/neck procedures - indicates a platform with versatile capabilities rather than a niche solution. This diversity of applications enhances the potential total addressable market and value proposition to healthcare facilities seeking multi-specialty utilization to maximize return on investment.
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s SSi Mantra surgical robotic system has been utilized to successfully perform more than 4,000 robotic surgeries across more than one hundred types of surgeries without any complications, injuries or mortalities. Of note, this milestone includes approximately 215 cardiac surgical procedures, of which six were successfully performed via telesurgery across India with the SSi Mantra 3 surgical robotic system.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “The milestone of 4,000 robotic surgeries successfully performed with our SSi Mantra surgical robotic system reflects its world-class quality, differentiated features, ease of use, and growing acceptance by leading physicians in India, where SS Innovations leads the market, and beyond. Our SSi Mantra systems are cleared to market in seven countries, and we are taking important steps to enter the United States and European Union markets. We continue along the pathway towards a European Union CE Mark decision as soon as late 2025 and a U.S. Food and Drug Administration decision as soon as the first half of 2026.”
Surgery types performed with the SSi Mantra to date:
- General Surgery
- Urology
- Gynecology
- Cardiac
- Gastrointestinal
- Thoracic
- Head and Neck
- Breast and Plastic
Countries where the SSi Mantra is approved to market:
- India
- Nepal
- Ecuador
- Guatemala
- Philippines
- Indonesia
- Ukraine
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@equityny.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@equityny.com
Media Contact:
press@ssinnovations.org
T: (212) 739-0300
FAQ
How many surgeries has the SSII SSi Mantra robotic system completed as of May 2025?
In which countries is the SSi Mantra surgical robot currently approved?
When does SSII expect to receive FDA approval for the SSi Mantra system?
What types of surgeries can be performed with the SSII SSi Mantra system?
When is SS Innovations expecting to receive EU CE Mark approval?
